2. ANTIFOLATE DRUGS
CLASSIFICATION AND PHARMACOKINETICS
Sulfonamides
The sulfonamides have a common chemical nucleus
resembling p-aminobenzoic acid (PABA).
3. SULFONAMIDES
ORALLY ABSORBABLE
short acting sulfisoxazole,
intermediate acting sulfamethoxazole,
long
acting sulfadoxine
ORALLY NONABSORBABLE
Sulfaguanidine, sulfasalazine
weakly absorbed after oral
administeration ,used for enteric fever
TOPICAL Sulfadiazine is used in burns
topically,
Sulfacetamide in ophthalmic
preparations
4. ANTIFOLATE DRUGS
MECHANISMS OF ACTION
1. Sulfonamides
• The sulfonamides are bacteriostatic
inhibitors of folic acid synthesis.
• As antimetabolites of PABA, they are
competitive inhibitors of dihydropteroate
synthase.
• The selective toxicity of sulfonamides
results from the inability of mammalian cells
to synthesize folic acid; they must use
preformed folic acid that is present in the
diet.
5. ANTIMETOBOLITE ANTIBIOTICS
They inhibit the folic acid synthesis
p-Aminobenzoic acid (PABA)
Dihydrofolic acid
Tetrahydrofolic acid
Purines
DNA
Dihydropteroate synthase
Dihydrofolate reductase
Sulfonamides (compete with PABA)
Trimethoprim, pyrimethamine
6.
7. ANTI-BACTERIAL SPECTRUM
Against enterobacter species in UTIs
Nocardia species
Sulfadiazine + pyrimethamine= used
for toxoplasmosis
Sulfadoxine + pyrimethamine = as
anti-malarial drug
8. RESISTANCE
Bacteria that obtain folate from
environment
Resistance may be due to plasmid
transfer or mutation
These involves following processes
1.Altered dihydropteroate synthetase
2. Decreased permeability
3.Enhanced production of PABA
9. PHARMACOKINETICS
Well absorbed orally
sulfasalazine is used as suppository for
treatment of ulcerative colitis
IV preparation are also available
Usually not applied topically due to risk of
allergic reaction
But in burn units, creams of silver sulfadiazine
or mafenide acetate used to inhibit sepsis
10. DISTRIBUTION
Bound to serum albumin, depends on pKa
value of drug
Smaller pKa, greater the binding
Distribute throughout the body including CSF
Also cross placental barrier
METABOLISM
Acetylated and conjugated in liver
Acetylated product is devoid of activity
11. EXCRETION
Through glomerular filtration
dose adjustment in renally compromised
patients
ADRs
Crystalluria/ stone formation in kidney that can
be prevented by adequate hydration and
alkalinization of urine
Hypersensitivity; rashes, angioedema or stevens-
johnson syndrome
12. Hematopoietic disturbances:
1. Hemolytic anemia
2. granulocytopenia
3. Aplastic anemia
4. Blood dyscrasias
Kernicterus
Billirubin in CNS of newborns as sulfa drugs
displace them from serum albumin
13.
14. Drug potentiation; warfarin and
methotrexate levels increased due to
displacement
Contraindication
Due to kernicterus, should be avoided in
newborns and pregnant women
15. TRIMETHOPRIM
Anti-bacterial spectrum similar to sulfonamides
Mostly used in combination with
sulfamethoxazole
20-50 folds more potent than sulfa drugs
MOA
Through inhibition of dihydrofolate reductase
leading to decreased availability of
tetrahydrofolate cofactor necessary for purine,
pyrimidine synthesis
17. PHARMACOKINETICS
Absorbed after oral administration
Widely distributed into body fluids and
tissues
Also penetration into CSF
Undergoes O-demethylation metabolism
60-80 % excreted unchanged in urine
18. ADRS
Folic acid deficiency which includes
megaloblastic anemia, leukopenia and
granulocytopenia
But these disorder can be reversed through
adminitration of folinic acid which cant enter in
bacteris
19. COTRIMOXAZOLE
The combination of trimethoprim
with sulfamethoxazole, called
cotrimoxazole
shows greater antimicrobial
activity than equivalent quantities of
either drug used alone
combination was selected because of
the similarity in the half-lives and
synergistic activity of the two
drugs.
20.
21. MECHANISM OF ACTION
inhibition of two sequential steps in
the synthesis of tetrahydrofolic
acid
Sulfamethoxazole inhibits the
incorporation of PABA into
dihydrofolic acid precursors,
Trimethoprim prevents reduction of
dihydrofolate to tetrahydrofolate
22. ANTIBACTERIAL SPECTRUM
Broader spectrum of antibacterial
action than the sulfa drugs
effective in treating following
infections
UTIs
RTIs
Pneumocystis jiroveci pneumonia
and ampicillin-
chloramphenicol-resistant systemic
salmonella infections.
23. MRSA so can be used for skin and soft
tissue infections
Also activity against Nocardia species
24. RESISTANCE
Resistance is less frequently
encountered than resistance to
either of the drugs alone
because simultaneous
resistance to both drugs is
required.
25. PHARMACOKINETICS
Administration of one part trimethoprim
to five parts of the sulfa drug
generally administered orally
Intravenous administration to
patients with severe pneumonia caused
by P. jiroveci.
Both agents distribute throughout the
body.
26. Trimethoprim concentrates in the
relatively acidic environment
Crosses BBB
Both drugs and metabolites
excreted in urine
27. ADVERSE DRUG REACTIONS
Dermatologic: Reactions involving the
skin are very common
Gastrointestinal: Nausea, vomiting, as
well as glossitis and stomatitis are not
unusual.
Hematologic: Megaloblastic anemia,
leukopenia, and thrombocytopenia
All these effects may be reversed by the
concurrent administration of folinic acid
28. Patients infected with human
immunodeficiency virus:
Immuno-compromised patients with
P. jiroveci pneumonia frequently show
drug-induced fever, rashes,
diarrhea, and/or pancytopenia.
Drug interactions:
Prolonged prothrombin time in
combination with warfarin
29. The plasma half-life of phenytoin may
be increased due to an inhibition of
its metabolism.
Methotrexate levels may rise due to
displacement from albumin-binding
sites by sulfamethoxazole.